Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 9/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 6/20 | 1.00 |
| ▸ | LMNA | P02545 | 5/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 1.00 |
| ▸ | HPGD | P15428 | 2/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.72 |
| ▸ | HTT | P42858 | 7/20 | 0.72 |
| ▸ | MAPT | P10636 | 9/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.67 |
| ▸ | MEN1 | O00255 | 4/20 | 0.66 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.62 |
| ▸ | USP2 | O75604 | 1/20 | 0.57 |
| ▸ | LIG1 | P18858 | 2/20 | 0.56 |
| ▸ | LIG3 | P49916 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19334542 | 0.91 | L3MBTL1 (0.83) | L3MBTL1KMT2ALMNASMN1; SMN2HPGD | |
| SCHEMBL15457450 | 0.75 | MEN1 (0.77) | L3MBTL1KMT2ALMNASMN1; SMN2KDM4E | |
| SCHEMBL31530751 | 0.73 | KDM4E (0.69) | L3MBTL1KMT2ALMNASMN1; SMN2KDM4E | |
| SCHEMBL21292751 | 0.72 | PHGDH (0.76) | L3MBTL1KMT2ALMNASMN1; SMN2KDM4E | |
| SCHEMBL21292753 | 0.72 | PHGDH (0.76) | L3MBTL1KMT2ALMNASMN1; SMN2KDM4E | |
| SCHEMBL13401821 | 0.72 | LIG1 (0.75) | L3MBTL1KMT2ALMNASMN1; SMN2HPGD | |
| SCHEMBL19298155 | 0.72 | LIG1 (1.00) | L3MBTL1KMT2ALMNASMN1; SMN2HPGD | |
| SCHEMBL13401789 | 0.72 | LIG1 (1.00) | L3MBTL1KMT2ALMNASMN1; SMN2HPGD | |
| SCHEMBL9458239 | 0.72 | KDM4E (0.67) | L3MBTL1KMT2ALMNASMN1; SMN2KDM4E | |
| SCHEMBL15457451 | 0.72 | KDM4E (0.69) | L3MBTL1KMT2ALMNASMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8445537-B2 | Compounds that inhibit human DNA ligases and methods of treating cancer | STC.UNM (US) | 2013-05-21 | — | — | US | disclosed |
| US-20100099683-A1 | COMPOUNDS THAT INHIBIT HUMAN DNA LIGASES AND METHODS OF TREATING CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-04-22 | — | — | US | disclosed |
| US-20100099683-A1 | COMPOUNDS THAT INHIBIT HUMAN DNA LIGASES AND METHODS OF TREATING CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099683-A1 | COMPOUNDS THAT INHIBIT HUMAN DNA LIGASES AND METHODS OF TREATING CANCER | LIG1, LIG4, LIG3 | L3MBTL1 379/4885KMT2A 1608/4885LMNA 785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.